Look back at pharma news in week to June 29

1 July 2018

By Barbara Obstoj-Cardwell. Editor

Last week’s clinical trial news included good and bad results. Roche’s latest data on Tecentriq was impressive in lung cancer, but Summit Therapeutics had a huge disappointment with its ezutromid in Duchenne muscular dystrophy (DMD). The US Food and Drug Administration’s approval of the first cannabinoid drug, GW Pharmaceuticals’ Epidiolex for rare forms of epilepsy caused a bit of s stir, while on the negative side, Pain Therapeutics looks set for another FDA rejection for pain drug Remoxy ER. On the M&A front, Novartis has at long last made a decision on the future of its eye care division Alcon.

Roche aims for first-mover edge in small cell lung cancer

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK